Book explores psilocybin for OCD treatment

A new book examines the potential of magic mushrooms to address obsessive-compulsive disorder, often called the doubting disorder.

The excerpt describes a scene in New York City where Adam Strauss debates between two MP3 players while holding his headphones cord. It draws on the idea of OCD as uncertainty and questions if psilocybin could help reduce that doubt.

Articoli correlati

A nurse playing Tetris on her phone with fading traumatic images, illustrating a study on Tetris reducing flashbacks.
Immagine generata dall'IA

New study: Tetris reduces flashbacks after trauma

Riportato dall'IA Immagine generata dall'IA

Researchers at Uppsala University have shown that a short treatment program involving Tetris can reduce intrusive memories in healthcare staff after trauma.

President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate access to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, including depression, anxiety, and PTSD. The order allocates $50 million in funding and instructs the FDA to prioritize reviews. Trump was joined by Health and Human Services Secretary Robert F. Kennedy Jr., Dr. Mehmet Oz, former Navy SEAL Marcus Luttrell, and podcast host Joe Rogan.

Riportato dall'IA

An 83-year-old woman with severe Alzheimer’s disease began speaking in full sentences and regained bladder control after taking a large dose of psilocybin. The changes occurred following a single session with the psychedelic compound derived from magic mushrooms. Researchers describe the case as dramatic but stress it is only one anecdotal report.

Researchers at MIT have discovered that chaotic laser light can self-organize into a highly focused pencil beam, enabling 3D imaging of the blood-brain barrier 25 times faster than current methods. The technique allows real-time observation of drugs entering brain cells without fluorescent tags. This breakthrough could speed up development of treatments for neurological diseases like Alzheimer's and ALS.

Riportato dall'IA

A large study tracking nearly 100,000 people in Sweden found that GLP-1 receptor agonists like semaglutide, sold as Ozempic and Wegovy, are associated with significantly fewer psychiatric hospital visits and reduced sick days due to mental health issues. Researchers observed drops of up to 47% in various mental health risks during drug use periods. The findings appear in The Lancet Psychiatry.

Questo sito web utilizza i cookie

Utilizziamo i cookie per l'analisi per migliorare il nostro sito. Leggi la nostra politica sulla privacy per ulteriori informazioni.
Rifiuta